Category: Corona Virus Vaccine

Page 66«..1020..65666768..8090..»

‘Misperception’ to associate stroke, heart attack with COVID-19 … – CNA

November 25, 2023

SINGAPORE: The association of COVID-19 vaccination with severe side effects like stroke, cancer and heart attack is a "misperception" that has to be corrected, said Health Minister Ong Ye Kung on Saturday (Nov 25).

Speaking at the official opening of Sembawang Polyclinic at 21 Canberra Link, Mr Ong said the Ministry of Health has been "very transparent" about the side effects and risks of all vaccinations.

He acknowledged thatwhen talking to residents about taking the COVID-19 vaccination at least once a year, the common reaction was to worry about side effects but the side effects were generally "a bit of ache in the arm or slight fever".

"But today, if residents are worried about severe side effects like stroke, cancer and heart attack and they associate this with vaccination, we have to correct this misperception," he added.

"In the case of COVID-19 vaccination, the risk of myocarditis, especially amongst younger males, is well established and we have been publishing the results.

"But even before COVID-19 and vaccination, every day, there are 60 Singaporeans who either suffer a heart attack or stroke, and six more Singaporeans require kidney dialysis."

Mr Ong said these cases "are driven by lifestyles over many years" via the accumulation of too much salt and sugar, lack of exercise and smoking.

"But when you have so many people suffering from stroke, heart attack and dialysis every day, after a while, they start associating and blaming it on vaccination."

"We cannot link the two," Mr Ong said, adding that if one is really worried about heart attack, cancer and stroke, they should adopt healthier lifestyles.

In May, Mr Ong responded to questions from Member of Parliament Tan Wu Meng (PAP-Jurong) aboutmyocarditis or heart inflammationafter COVID-19 vaccination, then saying there were 160 reports of myocarditis and pericarditis linked to the vaccines as of Apr 27.

This was out of over 17 million COVID-19 vaccine doses administered in Singapore.

Of the 160 cases, he said 32 per cent had initial symptoms reported within one day of vaccination, another 20 per cent reported within two days and another 24 per cent reported within one week.

"The majority of cases of myocarditis from vaccination are generally mild and respond to treatment," said Mr Ong to the House in May.

Excerpt from:

'Misperception' to associate stroke, heart attack with COVID-19 ... - CNA

‘Its not gone. Its changing. Its killing’: The COVID variants the WHO … – Euronews

November 25, 2023

There are several circulating subvariants of Omicron globally. But what are they and why are we not as concerned as WHO officials about it?

While the height of the pandemic may be over, the virus that causes COVID-19 continues to mutate with multiple variants circulating in every country.

Yet despite this, testing and surveillance have decreased, with experts urging people to keep taking the threat of this disease seriously.

"The world has moved on from COVID, and in many respects, that's good because people are able to stay protected and keep themselves safe, but this virus has not gone anywhere. It's circulating. It's changing, it's killing, and we have to keep up," Maria Van Kerkhove, the COVID-19 technical lead at the World Health Organization (WHO), told Euronews Next.

All the variants circulating today are sublineages of Omicron, a highly transmissible variant of COVID-19 that first emerged two years ago.

One sublineage, EG.5, also nicknamed Eris, currently represents more than half of the COVID-19 variants circulating globally. It was declared as a variant of interest by WHO back in August.

Cases of EG.5 increased over the summer, but it was recently outpaced in the United States by a closely related subvariant called HV.1. This subvariant now accounts for 29 per cent of the COVID-19 cases in the US, according to the latest figures from the Centres for Disease Control and Prevention (CDC).

"HV.1 is essentially a variant that's derived from EG.5.1 (and previously XBB.1.5) that's just accumulating a few mutations that allow it to better infect people who have immunity to SARS-CoV-2," Andrew Pekosz, a professor of molecular microbiology and immunology at Johns Hopkins University in the US, told Euronews Next.

Pekosz, who studies the replication of respiratory viruses, said that these variants likely emerged as random mutations as part of the natural evolution of viruses.

According to the European Centres for Disease Control and Prevention (ECDC), XBB 1.5-like variants such as EG.5 - or Eris - are currently dominant, making up about 67 per cent of cases in EU/EEA countries.

The prevalence of another Omicron sublineage called BA.2.86 has been "slowly increasing globally," according to WHO, which recently classified it as a "variant of interest". Its sequences were first reported in Israel and Denmark in July and August.

"BA.2.86, when it emerged, was something that was really concerning to scientists because it was a variant that had a large number of mutations, particularly in the spike protein, which is the target for the protective immunity that vaccines and infections give you," said Pekosz.

Scientists think that this variant likely originated in a person with a compromised immune system which allowed the virus to replicate and accumulate mutations at a faster rate, yet it hasnt come close to becoming dominant.

French authorities, however, recently said that most cases of BA.2.86 in the country were a new sublineage JN.1, which has been "detected in other countries but is mainly circulating in Europe and particularly in France".

It appears to have more mutations that make it more transmissible, Pekosz said.

RNA viruses like SARS-CoV-2, which causes COVID-19, are known to pick up mutations at a faster rate than other viruses "because they make more mistakes and don't have the ability to fix those mistakes," according to Pekosz.

SARS-CoV-2 and its spike protein also appear to tolerate a lot of mutations, similar to what scientists see with influenza.

But so far, while scientists pay attention to these mutations, they are not seeing changes in disease severity, and the tests we use still detect the virus.

These new variants will continue to emerge and "for the most frail in society, especially those with certain underlying health conditions, they will continue to contribute to hospitalisations and even deaths," said Andrew Pollard, a professor of infection and immunity at the University of Oxford.

However, Pollard does not expect them to "reboot a pandemic" as globally, there is strong population immunity from vaccination and prior infection.

While new families of COVID-19 are likely being generated by mutation," there hasnt been one "as successful as the Omicron variants which are dominating," he said. At least for now".

The worst-case scenario would be a new variant that spreads more quickly and causes more severe illness that the vaccines do not work against.

We don't take anything for granted. We have different scenarios that we're planning for in terms of the variants and their detection, said Van Kerkhove,who is also WHO's interim director for epidemic and pandemic preparedness and prevention.

At the moment these variants are not causing a new large surge in cases or hospitalisations, and while experts say that there is still enough sequencing for them to detect emerging variants, these efforts have decreased.

What we've lost recently is the ability to really get a sense of the whole diversity that's present in these virus populations, said Pekosz.

Van Kerkhove encouraged people to continue to get tested if they think they have COVID-19 because that allows scientists to track the virus and later sequence it to study possible mutations.

"If youre not tested, you cant be sequenced," she said.

Reductions in testing and sequencing as well as increased delays in getting the data "is very challenging for us and slows down our ability to do risk evaluations of each of these subvariants," she added.

Most importantly, even as the world moves on, experts recommend that people get vaccinated, wear masks in crowds or around people at higher risk of severe COVID-19, and get tested to prevent its further spread.

Read the original:

'Its not gone. Its changing. Its killing': The COVID variants the WHO ... - Euronews

Building a Stronger Tajikistan in the Wake of the COVID-19 Crisis … – ReliefWeb

November 25, 2023

For the past 30 years, the World Bank has partnered with Tajikistan to help boost economic growth, reduce poverty, and unleash the countrys full development potential. When COVID-19 hit, the World Bank financed the Tajikistan Emergency COVID-19 Project to support the Governments efforts to respond to the health, social, and economic impacts of the pandemic. Four rounds of financing for this project have strengthened the countrys intensive care capacity, vaccine deployment, and protection of vulnerable households, and strengthened pandemic prevention, preparedness, and response at the national and regional level, protecting the country against future shocks and helping build a resilient health sector.

Key Highlights

Challenge: Vulnerabilities Exposed by COVID-19

Tajikistan has experienced an improvement in living standards over the past two decades, with the poverty rate falling from 32 percent in 2009 to 13.4 percent in 2022. However, the country's undiversified economy, reliance on migrant remittances, and high risk of debt distress, make it more vulnerable to external shocks. The recent COVID-19 crisis significantly increased uncertainties and risks for Tajikistan, highlighting the health sector's weaknesses, and leading to increased poverty and food insecurity for the most vulnerable.

The **"Listening to Tajikistan" **survey monitored the well-being of people, focusing on the impacts of the COVID-19 pandemic,based on more than 17,000 interviews with people from all regions of the country. The survey found that people's economic well-being deteriorated severely in 2020; 40 percent of respondents reported that no family member was actively working in May 2020. Food security also deteriorated in 2020 as incomes fell and food prices went up, and in May and June 2020 over 35 percent of households said they had to reduce their food consumption. These impacts were exacerbated by a 20 percent decline in remittances, in a country where more than half of households rely on this source of income to buy food and other basic necessities.

Approach: From Pandemic Response to Prevention and Preparedness

June 4, 2023 marked 30 years of partnership between Tajikistan and the World Bank, and 29 years of Tajikistan belonging to the International Development Association (IDA). During this period, the World Bank **provided over $2.8 billion in support **for improvements to infrastructure, education, healthcare, poverty reduction, and more. These operations are providing better health services for the country's population by strengthening institutional capacity, providing training and equipment, addressing child malnutrition, and providing vaccination and other support against pandemics such as COVID-19.

At the onset of the COVID-19 outbreak, Tajikistan was one of the first countries in the world to receive emergency support from the World Bank, which worked with the country's Ministry of Health and Social Protection of the Population (MOHSP). An original IDA grant of $11.3 million was approved for the Emergency COVID-19 Project to: i) strengthen the country's capacity to provide intensive care to people sick with COVID-19 (e.g. through renovation and equipment for intensive care units); ii) help communities reduce infection (e.g. by providing personal protective equipment for health care workers, and information and behavior change communication for the general population); and iii) protect the vulnerable (e.g. with cash transfers to protect children vulnerable to malnutrition). This support was reinforced by three rounds of additional financing: $8.63 million for COVID-19 vaccines, $12.57 million in grant financing for additional cash transfers, strengthening of oxygen supply, and a stop-gap funding for routine child immunization (February 2021), and a $25 million grant for the procurement and provision of additional vaccines (March 2022).

The World Bank's focus has subsequently shifted towards addressing critical gaps in pandemic prevention, preparedness and response (PPR). Given the success of the national vaccination campaign and lower demand for COVID-19 vaccines, in 2023, the project was restructured to strengthen the country's sanitary and epidemiological services (SES), laboratory capacity, and digitalization of information systems. PPR is also part of the recently approved health project Millati Solim -- Health Nation.

At the regional level, this impetus is translating into initiatives like the Central Asia One Health Framework for Action. The World Bank is collaborating with several Central Asian countries on the Framework, which will help address three shared high-level goals: pandemic prevention and preparedness, the resilience of food systems, and improving regional trade and agricultural sector competitiveness.

Results: Crisis Response and Social Protection

The World Bank committed a total of $57.5 million under the Tajikistan Emergency COVID-19 Projectto help strengthen the country's response to the pandemic and support vaccine procurement and delivery. The results achieved around the three key areas of the project include:

"We are grateful for the efforts of the Government and the World Bank in providing modern facilities for us. It has been three days after my father's surgery. He is feeling better now," says Mirzosharif Sobirov, a resident of Tajikistan's Varzob district.

With World Bank support, Tajikistan was able to procure almost 900,000 doses of Moderna's COVID-19 vaccine. 98 percent of all adults - Tajikistan's COVID-19 vaccination target group (57 percent of the overall population) was vaccinated as of June 2023.

Visit link:

Building a Stronger Tajikistan in the Wake of the COVID-19 Crisis ... - ReliefWeb

COVID-19 is on the rise in Pueblo this winter. Here is what to know – Pueblo Chieftain

November 25, 2023

chieftain.com wants to ensure the best experience for all of our readers, so we built our site to take advantage of the latest technology, making it faster and easier to use.

Unfortunately, your browser is not supported. Please download one of these browsers for the best experience on chieftain.com

View original post here:

COVID-19 is on the rise in Pueblo this winter. Here is what to know - Pueblo Chieftain

Local program helps Covington businesses recover from COVID-19 – LINK nky

November 25, 2023

In the wake of the COVID-19 pandemic, the Northern Kentucky Community Action Commission created a program to help small businesses recover from the economic downturn.

Last September, the City of Covington gave $185,890 worth of American Rescue Plan Act funds to the Northern Kentucky Community Action Commission to identify and assist small and home-based businesses impacted by the COVID-19 pandemic. The newly created program was titled the Small Business Technical Assistance.

On Tuesday, the programs director Covington-based attorney Jamir Davis updated the commission on its progress. So far, the program has served 32 Covington small businesses, held over 75 one-on-one consultations, and assisted with the founding and registration of 13 businesses, including Golden Gelato, The Empanadas Box, DeeFelice Market and Upper Kutz barber shop.

All in all, wed definitely say the program was a success, Davis told the commission.

Business owners were required to answer a variety of questions to determine what kind of service was best suited to their specific situation.

As a part of our one-on-one consultations, we would really sit down with businesses and ask the hard questions, Davis said. What do you sell? What will people buy from you? What will you charge? How can customers pay you?

The program provides business owners with services such as assistance on properly registering their business with Covington and the state of Kentucky, budget creation, updating business financials, developing business plans and completing a financial literacy program.

The program is open to Covington residents who were negatively impacted by COVID-19, current small business owners, and those who aspire to start an unestablished business.

It was an easy sell to help businesses that were in need during COVID and we appreciate you hitting the ground and going out and finding those businesses and talking with them, Vice Mayor Ron Washington told Davis.

Read more here:

Local program helps Covington businesses recover from COVID-19 - LINK nky

Tourism in Europe is back after the COVID-19 lull and locals have … – Connecticut Public

November 25, 2023

Stand up for civility

This news story is funded in large part by Connecticut Publics Members listeners, viewers, and readers like you who value fact-based journalism and trustworthy information.

We hope their support inspires you to donate so that we can continue telling stories that inform, educate, and inspire you and your neighbors. As a community-supported public media service, Connecticut Public has relied on donor support for more than 50 years.

Your donation today will allow us to continue this work on your behalf. Give today at any amount and join the 50,000 members who are building a betterand more civilConnecticut to live, work, and play.

Read more here:

Tourism in Europe is back after the COVID-19 lull and locals have ... - Connecticut Public

Experts closely monitoring uptick in COVID-19 during holiday season – KSTP

November 25, 2023

As the season of gatherings and get-togethers begins, a warning from those tracking COVID-19 throughout the state comes along with it caution will be key to help turn an increasing trend around.

Right now, we are seeing an uptick, Dr. Susan Kline, of the University of Minnesotas Medical School, said, adding, It is increased compared to where weve been the last several weeks.

Dr. Kline said its not a dramatic increase, but one theyll be watching closely as the university and Minnesota Department of Health (MDH) are now in charge of tracking COVID-19 in the states wastewater.

The latest data available shows a 13-percent increase over the last two weeks, part of a slow rise that began in June. But, the state is nowhere near the levels tracked at the beginning of the year. Still, Dr. Kline says with the timing of the trend, people should lean on our experience about what we know about this virus.

If youve been exposed to somebody whos ill, especially if its someone with COVID, again, probably best to test yourself before you go to a holiday gathering, Dr. Kline said. If youre feeling well, and the test is negative, I think itd be okay to go [to a holiday gathering]. But, depending on how close your exposure was, you maybe should be wearing a mask.

She also suggests taking advantage of the tools at hand including Paxlovid, a medication meant to treat COVID-19 that needs a prescription. And, just this week, the federal government is sending free at-home COVID-19 tests again households can order up to eight tests, depending if they ordered the four offered earlier this year.

I think those [at-home COVID-19 tests] are probably the easiest and quickest tests that people can get their hands on at short notice, and theyre quite good, Dr. Kline said.

Order your free tests HERE.

Dr. Kline said its also not too late to get the COVID-19 vaccine for it to make an impact this season.

Continued here:

Experts closely monitoring uptick in COVID-19 during holiday season - KSTP

Valve CEO Gabe Newell Ordered to Attend In-Person Antitrust … – IGN

November 25, 2023

Gabe Newell has been ordered to attend an in-person deposition relating to Overgrowth developer Wolfire Games' antitrust lawsuit against Valve despite his request to do it remotely.

As reported by GI.biz, the Valve CEO had requested the remote deposition due to concerns regarding COVID-19, but the court said he presented "insubstantial evidence to suggest that he is at particularised risk of serious illness".

The order, which was filed on November 16 in the U.S. District Court for the Western District of Washington, included a statement from Wolfire Games which said Newell "is uniquely positioned to testify on all aspects of [Valve's] business strategy" and an in-person deposition "would allow [it] to adequately assess Newell's credibility".

It does offer some precautions to alleviate Newell's COVID-19 concerns, however, including that all courtroom participants must wear masks during the deposition. Newell must remove his mask when answering questions though.

Wolfire Games CEO David Rosen is leading a class-action lawsuit representing game developers against Valve, which asserts that the near dominance of Steam on the PC games market increases the prices of games due to Valve's service taking a 30% commission from the sale of each game.

Rosen said that his motivation for the lawsuit is that gamers and game developers are being harmed by Valve's conduct.

Image Credit: Olly Curtis/Future Publishing via Getty Images

Ryan Dinsdale is an IGN freelance reporter. He'll talk about The Witcher all day.

Read this article:

Valve CEO Gabe Newell Ordered to Attend In-Person Antitrust ... - IGN

4 out of 5 Mexicans who got a flu shot this year turned down Cuban and Russian COVID-19 vaccines – ABC News

November 25, 2023

Four out of five people in Mexico who got influenza shots so far this year turned down the government's recommendation they get Russian or Cuban COVID-19 boosters at the same time

November 21, 2023, 4:27 PM ET

2 min read

MEXICO CITY -- Four out of five people in Mexico who got influenza shots so far this year turned down the governments recommendation that they get Russian or Cuban COVID-19 boosters at the same time, officials said Tuesday.

Assistant Health Secretary Ruy Lpez Ridaura attributed the high refusal rate to people being reluctant to get two vaccines at the same time.

People have a certain reluctance to get simultaneous vaccinations, Lpez Ridaura said.

But the population eligible for flu and COVID-19 shots people over 60 and people with underlying health problems are considered high-risk, and Mexicans in those groups had extremely high take-up rates for Covid vaccines in 2021 and 2022, according to the Health Department.

Some people appear to simply distrust the Russian Sputnik and Cuban Abdala vaccines, both designed in 2020 for variants prevalent at the time.

It is an old antigen, it's as if they were going to give me an influenza vaccine from 2020, said Andreu Comas, a professor of medicine at the Autonomous University of San Luis Potosi. There are no studies regarding the effectiveness of both of these vaccines against the (current) variants.

Mexico has bought millions of doses of the Russian and Cuban vaccines. The original plan was to administer around 20 million shots, but only about 1.9 million people, or 9.5% of those eligible, have agreed to take them since the vaccination campaign started in mid-October.

In contrast, 10 million people got the influenza shot in the same period.

President Andrs Manuel Lpez Obrador has been a big supporter of Cuba, hiring Cuban doctors, buying vaccines and construction materials from Cuba and supplying oil to the island.

Meanwhile, Mexico has held up approval for Pfizer and Moderna COVID-19 boosters, both of which were designed to work against the COVID variants currently circulating. While those shots have been approved for use in the United States since September, they may not be available for Mexicans until 2024.

____

Follow APs coverage of Latin America and the Caribbean at https://apnews.com/hub/latin-america

See the original post here:

4 out of 5 Mexicans who got a flu shot this year turned down Cuban and Russian COVID-19 vaccines - ABC News

Is Novavax, the latecomer COVID vaccine, worth the wait? – Maryland Matters

November 23, 2023

Swabs from patients participating in a Novavax COVID vaccine trial await testing at the UW Medicine Retrovirology Lab at Harborview Medical Center on February 12, 2021, in Seattle, Washington. Photo by Karen Ducey/Getty Images.

Erin Kissane, a co-founder of the COVID Tracking Project, rolled up her sleeve for the Novavax COVID-19 vaccine in mid-October soon after it was finally recommended in the United States. Like many people with autoimmune diseases, she wants to protect herself from a potentially devastating COVID infection.

Kissanes autoimmune arthritis seems to make her susceptible to unusual vaccine side effects. After getting an mRNA booster last year, her joints ached so painfully that her doctor prescribed steroids to dampen the inflammation. She still considers the mRNA vaccines miraculous, knowing COVID could be far worse than temporary aches.

Nonetheless, when the pain subsided, she pored through studies on Gaithersburg-based Novavaxs shot, a vaccine that is based on proteins rather than mRNA and has been used since early 2022 in other countries. Data from the United Kingdom found that people more frequently reported temporary reactions like low fevers, fatigue, and pain as their immune system ramped up in the days following booster vaccination with Modernas mRNA vaccine versus the one by Pfizer. And those boosted with Novavaxs had fewer complaints than either of those. That finding was corroborated in an analysis of international data published last year.

Such studies have driven people with long COVID and chronic fatigue syndrome (also known as myalgic encephalomyelitis, or ME/CFS) to seek out Novavax, too, since the FDA and the Centers for Disease Control and Prevention greenlighted Novavaxs vaccine updated to protect against recent omicron coronavirus variants about three weeks after recommending updated mRNA vaccines in September.

Waiting paid off for Kissane, whose arm was briefly sore. It was a dramatically different experience for me, she said. I hope that plays out for others.

Another group who waited on Novavax are biologists who geek out over its technology. When asked why he opted for Novavax, Florian Krammer, a virologist at the Icahn School of Medicine at Mount Sinai, replied on X, formerly known as Twitter: Because I am [a] vaccine nerd, I like insect cell produced vaccines.

Whereas mRNA vaccines direct the body to produce spike proteins from the coronavirus SARS-CoV-2, which then train a persons immune system to recognize and fight the virus, Novavax simply injects the proteins. These proteins are grown within moth cells in a laboratory, while other protein-based shots use cells from mammals. And Novavax has said that a special ingredient derived from the bark of Chilean soapbark trees enhances the vaccines power.

Research suggests that the Novavax vaccine is about as safe and effective as the mRNA shots. Its main disadvantage is arriving late to the scene. Vaccine uptake has plummeted since the first shots became widely available in 2021. Nearly 70% of people got the primary vaccines, compared with fewer than 20% opting for the mRNA COVID boosters released last year. Numbers have dwindled further: As of Oct. 17, only 5% of people in the United States had gotten the latest COVID vaccines, according to the Department of Health and Human Services.

Daniel Park, an epidemiologist at George Washington University, said low rates might improve if people who felt lousy after their last mRNA shots gave Novavax a try. It protects against severe illness, but researchers struggle to specify just how effective this and other vaccines are, at this point, because studies have gotten tricky to conduct: New coronavirus variants continuously emerge, and people have fluctuating levels of immunity from previous vaccines and infections.

Still, a recent study in Italy suggests that Novavax is comparable to mRNA vaccines. It remained more than 50% effective at preventing symptomatic COVID four months after vaccination. Some data suggests that mixing and matching different types of vaccines confers stronger protection although other studies have found no benefit.

Given all this, Park held out for the Novavax vaccine on account of its potentially milder side effects. Between a demanding full-time job and two young kids at home, I wanted to stay operational, he said. His arm was sore, but he didnt have the 24-hour malaise accompanying his last mRNA shot.

Most people dont strike a fever after mRNA shots. Even when they do, it is brief and therefore far less detrimental than many cases of COVID. In fact, most reactions are so minor that theyre hard to interpret. During clinical trials on mRNA vaccines, for example, up to a third of people in the placebo group reported fatigue and headaches after injection.

People with ME/CFS and long COVID a potentially debilitating condition that persists months after a COVID infection have responded to COVID vaccinations in a wide variety of ways. Most participants with long COVID in an 83-person Canadian study said their levels of fatigue, concentration, and shortness of breath improved following vaccination. Inflammatory proteins that have been linked to long COVID dropped as well.

However, larger studies have yet to corroborate the hopeful finding. Jennifer Curtin, a doctor who co-founded a telehealth clinic focused on long COVID and ME/CFS, called RTHM, said vaccines seem to temporarily aggravate some patients conditions. To learn how Novavax compares, she posted polls on X in late October asking if people with long COVIDor ME/CFS felt that their symptoms worsened, improved, or stayed the same after Novavax. Most replied: unchanged.

Its not scientific, but we need to figure it out since these folks dont want to get COVID, Curtin said. My patients are all wondering about what vaccine to get right now.

Adding to the uncertainty, the rollout of Novavax and mRNA vaccines has been bumpy as pharmacies struggle to predict demand and insurance companies figure out how to reimburse providers for the shots. Unlike previous vaccine offerings, these options are no longer fully covered by the federal government. A testament to this seasons struggle to get vaccinated is that at least one do-gooder has created an online tool to find open appointments for Novavax.

Buoyed by anecdotes of relief from others with long COVID, Hayley Brown, a researcher at the Center for Economic and Policy Research who has the condition, opted for Novavax recently. Unfortunately, her symptoms have flared. She said a temporary discomfort will still be preferable to risking another infection. As someone with long COVID, the idea of getting COVID again is terrifying.

KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFFan independent source of health policy research, polling, and journalism. Learn more about KFF.

Subscribe to KFF Health News free Morning Briefing.

View original post here:

Is Novavax, the latecomer COVID vaccine, worth the wait? - Maryland Matters

Page 66«..1020..65666768..8090..»